Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl Acad. Sci. USA 98, pp.10869-10874, 2001. ,
DOI : 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer, JNCI: Journal of the National Cancer Institute, vol.106, issue.8, p.152, 2014. ,
DOI : 10.1093/jnci/dju152
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001. ,
DOI : 10.1056/NEJM200103153441101
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2???Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group, Journal of Clinical Oncology, vol.23, issue.19, pp.4265-4274, 2005. ,
DOI : 10.1200/JCO.2005.04.173
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1673-1684, 2005. ,
DOI : 10.1056/NEJMoa052122
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1659-1672, 2005. ,
DOI : 10.1056/NEJMoa052306
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial, Journal of Clinical Oncology, vol.34, issue.10, pp.1034-1042, 2014. ,
DOI : 10.1200/JCO.2015.62.1797
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes, Journal of Clinical Oncology, vol.30, issue.15, pp.1796-1804, 2012. ,
DOI : 10.1200/JCO.2011.38.8595
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer, Breast Cancer Research, vol.13, issue.1, p.11, 2013. ,
DOI : 10.1016/S1470-2045(11)70336-9
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, The Lancet, vol.384, issue.9938, pp.164-172, 2014. ,
DOI : 10.1016/S0140-6736(13)62422-8
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib, Journal of Clinical Oncology, vol.34, issue.6, pp.542-549, 2015. ,
DOI : 10.1200/JCO.2015.62.1268
PTEN, PIK3CA, p-AKT, and p-p70S6K Status, The American Journal of Pathology, vol.177, issue.4, pp.1647-1656, 2010. ,
DOI : 10.2353/ajpath.2010.090885
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947262
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab, Annals of Oncology, vol.23, issue.8, pp.2034-2042, 2012. ,
DOI : 10.1093/annonc/mdr546
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2???Positive, First-Line Metastatic Breast Cancer, Journal of Clinical Oncology, vol.32, issue.33, pp.3753-3761, 2014. ,
DOI : 10.1200/JCO.2013.54.5384
Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti???Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer, Journal of Clinical Oncology, vol.32, issue.29, pp.3212-3220, 2014. ,
DOI : 10.1200/JCO.2014.55.7876
Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2???Targeted Therapies in Breast Cancer, Journal of Clinical Oncology, vol.33, issue.12, pp.1334-1339, 2015. ,
DOI : 10.1200/JCO.2014.55.2158
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers, Breast Cancer Research, vol.10, issue.2, p.15, 2009. ,
DOI : 10.1186/bcr2124
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial, Annals of Oncology, vol.26, pp.2429-2436, 2015. ,
DOI : 10.1093/annonc/mdv395
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.8, pp.741-748, 2013. ,
DOI : 10.1016/S1470-2045(13)70225-0
Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial, Annals of Oncology, vol.25, issue.8, pp.1563-1570, 2014. ,
DOI : 10.1093/annonc/mdu177
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer, Journal of Clinical Oncology, vol.25, issue.1, pp.118-145, 2007. ,
DOI : 10.1200/JCO.2006.09.2775
Supplemental information: the genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, vol.486, pp.346-352, 2012. ,
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes, Journal of Clinical Oncology, vol.27, issue.8, pp.1160-1167, 2009. ,
DOI : 10.1200/JCO.2008.18.1370
A refined molecular taxonomy of breast cancer, Oncogene, vol.10, issue.9, pp.1196-1206, 2011. ,
DOI : 10.1038/nature09515
URL : https://hal.archives-ouvertes.fr/inserm-00611752
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers, Nature Medicine, vol.5, issue.8, pp.907-913, 2009. ,
DOI : 10.4049/jimmunol.174.10.6477
The landscape of cancer genes and mutational processes in breast cancer, Nature, vol.135, pp.400-404, 2012. ,
DOI : 10.2307/2344614
Mutational Processes Molding the Genomes of 21 Breast Cancers, Cell, vol.149, issue.5, pp.979-993, 2012. ,
DOI : 10.1016/j.cell.2012.04.024
Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer, Breast Cancer Research, vol.7, issue.S2, p.30, 2007. ,
DOI : 10.1186/bcr1174
TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance, Clinical Cancer Research, vol.20, issue.13, pp.3569-3580, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-2943
Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib, PLoS ONE, vol.6, issue.10, p.26760, 2011. ,
DOI : 10.1371/journal.pone.0026760.s007
OncoCis: annotation of cis-regulatory mutations in cancer, Genome Biol, vol.15, p.485, 2014. ,
High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer, Breast Cancer Research, vol.10, issue.3, p.25, 2010. ,
DOI : 10.1186/bcr2124
Genome profiling of ERBB2-amplified breast cancers, BMC Cancer, vol.61, issue.1, p.539, 2010. ,
DOI : 10.1136/jcp.2007.052431
Novel patterns of genome rearrangement and their association with survival in breast cancer, Genome Research, vol.16, issue.12, pp.1465-1479, 2006. ,
DOI : 10.1101/gr.5460106
Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes, Cell, vol.153, issue.4, pp.919-929, 2013. ,
DOI : 10.1016/j.cell.2013.04.010
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation, Cancer Research, vol.72, issue.21, pp.5454-5462, 2012. ,
DOI : 10.1158/0008-5472.CAN-12-1470
The stability of broken ends of chromosomes in Zea Mays, Genetics, vol.26, pp.234-282, 1941. ,
Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution, Genome Research, vol.17, issue.9, pp.1296-1303, 2007. ,
DOI : 10.1101/gr.6522707
The patterns and dynamics of genomic instability in metastatic pancreatic cancer, Nature, vol.22, issue.7319, pp.1109-1113, 2010. ,
DOI : 10.1038/nature09460
A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications, Breast Cancer Research, vol.42, issue.Suppl 2, p.150, 2012. ,
DOI : 10.1038/ng.669
An algorithmic approach for breakagefusion-bridge detection in tumor genomes, Proc. Natl Acad. Sci. USA, pp.5546-5551, 2013. ,
Modeling the evolution space of breakage fusion bridge cycles with a stochastic folding process, Journal of Mathematical Biology, vol.110, issue.14, pp.47-86, 2015. ,
DOI : 10.1007/978-3-319-05269-4_32
Double Minute Chromosomes in Glioblastoma Multiforme Are Revealed by Precise Reconstruction of Oncogenic Amplicons, Cancer Research, vol.73, issue.19, pp.6036-6045, 2013. ,
DOI : 10.1158/0008-5472.CAN-13-0186
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, vol.19, issue.2, pp.185-193, 2003. ,
DOI : 10.1093/bioinformatics/19.2.185
affy--analysis of Affymetrix GeneChip data at the probe level, Bioinformatics, vol.20, issue.3, pp.307-315, 2004. ,
DOI : 10.1093/bioinformatics/btg405
The importance of gene-centring microarray data, The Lancet Oncology, vol.11, issue.8, pp.719-720, 2010. ,
DOI : 10.1016/S1470-2045(10)70174-1
Computation of Gene Expression-Based Signatures in Breast Cancer. R package version 2.5.2, 2015. ,
BRB Array Tools Users Guide Technical Reports Biometric Research Branch, National Cancer Institute, 2006. ,
beadarray: R classes and methods for Illumina bead-based data, Bioinformatics, vol.23, issue.16, pp.2183-2184, 2007. ,
DOI : 10.1093/bioinformatics/btm311
Jetset: selecting the optimal microarray probe set to represent a gene, BMC Bioinformatics, vol.12, issue.1, p.474, 2011. ,
DOI : 10.1186/1471-2105-12-474
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, vol.98, issue.7269, pp.108-112, 2009. ,
DOI : 10.4049/jimmunol.167.9.4948
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783335
Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios, BMC Bioinformatics, vol.9, issue.1, p.409, 2008. ,
DOI : 10.1186/1471-2105-9-409
Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays, Genome Biology, vol.10, issue.11, p.128, 2009. ,
DOI : 10.1186/gb-2009-10-11-r128
URL : https://hal.archives-ouvertes.fr/inserm-00663915
Analyzing cancer samples with SNP arrays, Methods Mol. Biol, vol.802, pp.57-72, 2012. ,
Fast and accurate short read alignment with Burrows-Wheeler transform, Bioinformatics, vol.25, issue.14, pp.1754-1760, 2009. ,
DOI : 10.1093/bioinformatics/btp324
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705234
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data, Genome Research, vol.20, issue.9, pp.1297-1303, 2010. ,
DOI : 10.1101/gr.107524.110
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nature Biotechnology, vol.27, issue.3, pp.213-219, 2013. ,
DOI : 10.1093/bioinformatics/btr446
Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor, Bioinformatics, vol.26, issue.16, pp.2069-2070, 2010. ,
DOI : 10.1093/bioinformatics/btq330
An atlas of active enhancers across human cell types and tissues, Nature, vol.45, issue.7493, pp.455-461, 2014. ,
DOI : 10.1093/bioinformatics/btq033
Summarizing and correcting the GC content bias in high-throughput sequencing, Nucleic Acids Research, vol.40, issue.10, p.72, 2012. ,
DOI : 10.1093/nar/gks001
Fast Computation and Applications of Genome Mappability, PLoS ONE, vol.39, issue.Suppl 1, p.30377, 2012. ,
DOI : 10.1371/journal.pone.0030377.t002
URL : https://hal.archives-ouvertes.fr/inserm-00664289
Reconstructing Breakage Fusion Bridge Architectures Using Noisy Copy Numbers, Journal of Computational Biology, vol.22, issue.6, pp.577-594, 2015. ,
DOI : 10.1089/cmb.2014.0166
Estimation of rearrangement phylogeny for cancer genomes, Genome Research, vol.22, issue.2, pp.346-361, 2012. ,
DOI : 10.1101/gr.118414.110
Multiple Correspondence Analysis and Related Methods, 2006. ,
DOI : 10.1201/9781420011319
ADE-4: a multivariate analysis and graphical display software, Statistics and Computing, vol.7, issue.1, pp.75-83, 1997. ,
DOI : 10.1023/A:1018513530268
URL : https://hal.archives-ouvertes.fr/hal-00434994
Sur le calcul des taux d'inertie dans l'analyse d'un questionnaire, pp.377-378, 1979. ,
Interpreting multiple correspondence analysis as a multidimensional scaling method, Marketing Letters, vol.25, issue.3, pp.259-272, 1992. ,
DOI : 10.1007/BF00994134